CTOs on the Move

Cartography Biosciences

www.cartography.bio

 
Cartography Biosciences is focused on developing tumor-selective therapeutics that are based on a unique genomics and computational platform. Cartography`s platform integrates data from proprietary sample sourcing relationships, an industry-leading comprehensive reference atlas, and our target identification algorithms to identify the cells of interest and the single or pairs of targets that are most specific to the intended target cells. Cartography is unlocking the full potential of immunotherapy by discovering and developing therapeutics as precise as their targets. To learn more about Cartography and our mission to treat every patient with cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cartography.bio
  • 220 East Grand Avenue 2nd Floor
    South San Francisco, CA USA 94080
  • Phone: 833.318.4749

Executives

Name Title Contact Details

Similar Companies

AgriMetis

AgriMetis discovers, develops, and delivers innovative crop protection products. Our scientific approach is multidisciplinary and integrated which allows AgriMetis to exploit areas of chemical space and production routes that are inaccessible to others. The AgriMetis platform delivers rapid, efficient, and optimal solutions to challenges in crop protection by bringing innovative products and their production processes to the market faster for the $56 billion agricultural chemical industry.

AlgiKnit

AlgiKnit is a collective of designers and scientists who work across disciplines to create new material possibilities. Were creating sustainable, algae-derived, biodegradable yarns and textiles to remediate harmful cycles of fast fashion. Bui...

Immunomic Therapuetics

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing ground-breaking next generation LAMP DNA vaccines, beginning with allergy, cancer and infectious disease.

Hansa Biopharma

We are dedicated to developing lifesaving and life-altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.

DynamiCure

DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease. We are driven by science and passionate about advancing patient care, translating pioneering new insights on immuno-normalization into a pipeline of innovative candidates with first-in-class and best-in-class potential. Since our founding in 2019, we have identified and obtained exclusive global rights to several novel targets and are rapidly advancing into the clinic both monoclonal and bispecific therapeutic antibody candidates.